Mesenchymal stem cell therapies for liver cirrhosis: MSCs as “conducting cells” for improvement of liver fibrosis and regeneration
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem cells (MSCs) can be cultured relatively easily and can be obtained not only from the bone marrow, but also from medical waste such as adipose tissue and umbilical cord tissue. Because of its low antigenicity, allogeneic MSC injection is safe. MSCs have been evaluated in more than 900 clinical trials in a variety of fields, with more than 50 clinical trials related to liver diseases. Experiments have suggested that MSCs function as “conducting cells” to affect various “effective cells” such as T cells, B cells, and macrophages. Recent clinical trials have focused on allogeneic MSCs. Thus, studies are needed to determine the most effective cell source, culture conditions, cell numbers, administration frequency, administration route, cost, safety, and liver disease treatments. Recently, the functions of exosomes have gained attention, and cell-free therapy may become possible as an alternative therapy for liver disease. In this review, we introduce general information, mechanism, representative clinical study data, recently started or planned clinical trials, and possibility of cell-free therapy of MSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Concise review: MSC-derived exosomes for cell-free therapy
Phinney, D. G., & Pittenger, M. F. (2017) · Stem Cells · doi:10.1002/stem.2575 · Cited by 1,834
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
The microRNA regulatory landscape of MSC-derived exosomes: a systems view
Ferguson, S. W., Wang, J., Lee, C. J., Liu, M., Neelamegham, S., Canty, J. M., & Nguyen, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-19581-x · Cited by 360
Suk, K. T., Yoon, J., Kim, M. Y., Kim, C. W., Kim, J. K., Park, H., Hwang, S. G., Kim, D. J., Lee, B. S., Lee, S. H., et al. (2016) · Hepatology · doi:10.1002/hep.28693 · Cited by 303
Lin, B., Chen, J., Qiu, W., Wang, K., Xie, D., Chen, X., Liu, Q., Peng, L., Li, J., Mei, Y., et al. (2017) · Hepatology · doi:10.1002/hep.29189 · Cited by 288
Watanabe, Y., Tsuchiya, A., Seino, S., Kawata, Y., Kojima, Y., Ikarashi, S., Starkey Lewis, P. J., Lu, W.-Y., Kikuta, J., Kawai, H., et al. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0105 · Cited by 155
Self-citation
Cited by
Cell therapy for advanced liver diseases: repair or rebuild
Dwyer, B. J., Macmillan, M. T., Brennan, P. N., & Forbes, S. J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.014 · Cited by 141
Azizsoltani, A., Hatami, B., Zali, M. R., Mahdavi, V., Baghaei, K., & Alizadeh, E. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115777 · Cited by 40
Mesenchymal stem cell-based Smad7 gene therapy for experimental liver cirrhosis
Su, D.-N., Wu, S.-P., & Xu, S.-Z. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01911-4 · Cited by 33
Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials
Huang, W.-C., Li, Y.-C., Chen, P.-X., Ma, K. S.-K., & Wang, L.-T. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04127-y · Cited by 29
Zhu, D., Sun, Z., Wei, J., Zhang, Y., An, W., Lin, Y., & Li, X. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s450284 · Cited by 17
Metadata
- Authors
- Tsuchiya, A., Takeuchi, S., Watanabe, T., Yoshida, T., Nojiri, S., Ogawa, M., & Terai, S.
- Venue
- Inflammation and Regeneration
- Published
- 2019-09-09
- Volume
- 39
- Issue
- 1
- Pages
- 18-18
- ISSN
- 1346-8022 (ISSN-L)
- 1880-8190
- OpenAlex
- W2972860306
- Cited by
- 112
- References
- 6
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal stem cell therapies for liver cirrhosis: MSCs as “conducting cells” for improvement of liver fibrosis and regeneration. https://app.cochat.ai/papers/10.1186/s41232-019-0107-z
- The paper
- Tsuchiya, A., Takeuchi, S., Watanabe, T., Yoshida, T., Nojiri, S., Ogawa, M., & Terai, S. (2019). Mesenchymal stem cell therapies for liver cirrhosis: MSCs as “conducting cells” for improvement of liver fibrosis and regeneration. Inflammation and Regeneration. https://doi.org/10.1186/s41232-019-0107-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.